Ryan Potts

What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. science.org/doi/10.1126/sc… #mycompnay

Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small Molecules biorxiv.org/content/10.648… #biorxiv_biochem

Functional inactivation of the telomerase chaperone TCAB1 primes cells for the activation of ALT in osteosarcoma biorxiv.org/content/10.648… #biorxiv_cancer

Selinexor is an allosteric degrader: it stabilizes XPO1/CRM1 to expose a cryptic ASB8 E3 ligase site, triggering ubiquitination. Led by Casey Wing, Joyce Fung & Bert Kwanten. #TargetedDegradation #Allostery nature.com/articles/s4158…

Mapping the latent CRBN-molecular glue degrader interactome biorxiv.org/content/10.648… #biorxiv_molbio

Orthosteric Molecular Glue Inhibits COP9 Signalosome with Substrate-Dependent Potency biorxiv.org/content/10.110… #biorxiv_molbio

Thrilled to share that I have joined @Amgen as the inaugural Amgen Science Fellow. I look forward to partnering with colleagues to design next-gen therapeutic by integrating AI/ML with high throughput synthetic biology platforms. linkedin.com/posts/drhoward…

Legend David Baltimore died yesterday. He understood the way things should work: "the real contribution of @MIT is that it doesn't take itself too seriously. It takes ideas seriously, but the people are relatively informal. They are not self-aggrandizing the way academics can be.

Thrilled to share our work to find natural products that inhibit β-catenin! This is the result of an amazing collaboration with @theNCI Natural Products Branch and shows the power of 'up' assays to find new and interesting molecules! biorxiv.org/content/10.110…

A new #ScienceReview looks at a different approach to drug discovery that may enable drugging of unconventional targets through stabilization of macromolecular complexes with molecules known as “LOCKTACs.” Learn more: scim.ag/4lAiKmF

Great to see our two in-house developed kinetic stabilizers, Tolcapone and PITB, against transthyretin amyloidoses cited as examples of an emerging therapeutic class: LOCKTACS. science.org/doi/10.1126/sc…

Talking of @amgen they also have cool LYMTACs: chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization & degradation nature.com/articles/s4146…

Degradation without E3s? Cool approach here - molecules that drag membrane proteins into lysosomes for degradation Might help get around KRASi resistance

@CKRamsoomair @ScienceMagazine Thanks!

@pottslab @ScienceMagazine Really interesting idea! 💡

What if treating disease meant stabilizing biology, not blocking it? We explore that idea in @ScienceMagazine with LOCKTAC molecular glues, a new class of molecules that stabilize natural interactions to either boost or block biology. science.org/doi/10.1126/sc… #mycompnay

@potthofflab @ScienceMagazine Thanks Matt.

@pottslab @ScienceMagazine Very nice work.

Amgen’s LOCKTAC molecular glues are changing how we target disease. 🔬 AMG 193, now in clinical trials, is designed to lock PRMT5 to MTA in MTAP-deleted tumors. Read more about how Amgen is working to innovate in this space.

Check out how we repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @nalawansha and team! #mycompany nature.com/articles/s4146…

From decoding the genome’s “dark matter” to designing next-gen medicines, @HowardYChang is the ideal leader for @Amgen Research. Tackling the toughest problems in therapeutic science requires deep insights into human biology, creative new technologies in molecular biology, comfort in computation, and a wiring for collaboration. Can think of nobody better to lead therapeutics discovery. Let's gooooo! #MyCompany Read more: nature.com/articles/d4157…

The passing Of Dave Mangelsdorf is a terrible loss for his family, friends and the science world. Davo will never be forgotten. 😢 chapelgazette.cfd/david-mangelsd…

Ray Deshaies has a new piece in Nature Reviews Drug Discovery on how multispecific drugs are reshaping pharmacology. During his time at @Amgen, Ray challenged us to rethink what molecules could do, especially with induced proximity. #MyCompany nature.com/articles/s4157…